Press release
Oncolytic Virus Cancer Therapy Pipeline Outlook, FDA Approvals, Clinical Trials and Companies 2024
Key Takeaways from the Oncolytic Virus Cancer Therapy Pipeline Report
* DelveInsight's Oncolytic Virus Cancer Therapy pipeline report depicts a robust space with 120+ active players working to develop 125+ pipeline therapies for Oncolytic Virus Cancer Therapy treatment.
* The leading Oncolytic Virus Cancer Therapy Companies working in the market include Genelux Corporation, Candel Therapeutics, CG Oncology, DNAtrix, SillaJen Biotherapeutics, Oncolytics Biotech, Wuhan Binhui Biotechnology, Oryx GmbH, Jiangsu Sinorda Biomedicine Co., Ltd, Elicera Therapeutics, Orgenesis, Replimune, Immvira Pharma, ViroCure, GeneMedicine, PsiOxus Therapeutics, Vyriad, VCN Biosciences, Beijing Syngentech, Turnstone Biologics, and others.
* Promising Oncolytic Virus Cancer Therapy in the various stages of development include ONCOS-102, gemcitabine, VRT106, CG0070, Keytruda, pembrolizumab, TILT-123, and others.
* April 2024:- Guangzhou Virotech Pharmaceutical Co., Ltd.- A Phase I Clinical Study to Evaluate the Safety, Tolerability, Biodistribution Characteristics, Biological Effects and Initial Efficacy of Recombinant Oncolytic Virus M1 for Injection (VRT106) in the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors.
* April 2024:- Mridula George, MD- This is a phase 2 study to evaluate the safety and efficacy of the combination of INCMGA00012 and pelareorep and to see how well they work in treating patients with triple negative breast cancer that has spread to other parts of the body (metastatic).
Request a sample and discover the recent advances in Oncolytic Virus Cancer Therapy treatment drugs @ Oncolytic Virus Cancer Therapy Pipeline Outlook Report [https://www.delveinsight.com/sample-request/oncolytic-virus-cancer-therapy-pipeline-insight-2021?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Oncolytic Virus Cancer Therapy Overview
Oncolytic virotherapy is a treatment of using a virus that can replicate itself to kill cancer cells. There are many species of viruses, but not all of them can be designed to be an oncolytic virus (OV). The typical features of these OVs must include being non-pathogenic, the ability to target and kill the cancer cells, and the capacity of being transformed to express tumor-killing factors through genetic engineering methods. Tumor selectivity could be concerned with the level of receptor-mediated cell entry, intracellular antiviral responses, or restriction factors that determine the susceptibility of the infected cell that leads to viral gene expression and replication.
Oncolytic Virus Cancer Therapy Emerging Drugs Profile
* Olvi-Vec: Genelux Corporation
* CAN-2409: Candel Therapeutics
* CG0070: CG Oncology
* Pelareorep: Oncolytics Biotech
* ParvOryx: Oryx GmbH
* SND005: Jiangsu Sinorda Biomedicine
* VCN-01: VCN Biosciences
Find out more about Oncolytic Virus Cancer Therapy treatment drugs @ Drugs for Oncolytic Virus Cancer Therapy Treatment [https://www.delveinsight.com/sample-request/oncolytic-virus-cancer-therapy-pipeline-insight-2021?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Oncolytic Virus Cancer Therapy Therapeutics Assessment
There are approx. 120+ key Oncolytic Virus Cancer Therapy companies which are developing the therapies for Oncolytic Virus Cancer Therapy. The Oncolytic Virus Cancer Therapy companies which have their Oncolytic Virus Cancer Therapy drug candidates in the most advanced stage, i.e. phase III include, Genelux Corporation.
DelveInsight's Oncolytic Virus Cancer Therapy report covers around 125+ products under different phases of clinical development like
* Late stage products (Phase III)
* Mid-stage products (Phase II)
* Early-stage product (Phase I) along with the details of
* Pre-clinical and Discovery stage candidates
* Discontinued & Inactive candidates
Learn more about the emerging Oncolytic Virus Cancer Therapy pipeline therapies @ Oncolytic Virus Cancer Therapy Clinical Trials [https://www.delveinsight.com/sample-request/oncolytic-virus-cancer-therapy-pipeline-insight-2021?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Oncolytic Virus Cancer Therapy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Intranasal
* Intravenous
* Oral
* Oral/Intravenous
* Parenteral
* Subcutaneous
* Subcutaneous/Intramuscular
Oncolytic Virus Cancer Therapy Products have been categorized under various Molecule types such as
* Oncolytic Viruse
Oncolytic Virus Cancer Therapy Companies
Genelux Corporation, Candel Therapeutics, CG Oncology, DNAtrix, SillaJen Biotherapeutics, Oncolytics Biotech, Wuhan Binhui Biotechnology, Oryx GmbH, Jiangsu Sinorda Biomedicine Co., Ltd, Elicera Therapeutics, Orgenesis, Replimune, Immvira Pharma, ViroCure, GeneMedicine, PsiOxus Therapeutics, Vyriad, VCN Biosciences, Beijing Syngentech, Turnstone Biologics, and others.
Dive deep into rich insights for new drugs for Oncolytic Virus Cancer Therapy Treatment, visit @ Oncolytic Virus Cancer Therapy Drugs [https://www.delveinsight.com/sample-request/oncolytic-virus-cancer-therapy-pipeline-insight-2021?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Oncolytic Virus Cancer Therapy Pipeline Report
* Coverage- Global
* Oncolytic Virus Cancer Therapy Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Oncolytic Virus Cancer Therapy Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
* Oncolytic Virus Cancer Therapy Companies- Genelux Corporation, Candel Therapeutics, CG Oncology, DNAtrix, SillaJen Biotherapeutics, Oncolytics Biotech, Wuhan Binhui Biotechnology, Oryx GmbH, Jiangsu Sinorda Biomedicine Co., Ltd, Elicera Therapeutics, Orgenesis, Replimune, Immvira Pharma, ViroCure, GeneMedicine, PsiOxus Therapeutics, Vyriad, VCN Biosciences, Beijing Syngentech, Turnstone Biologics, and others.
* Oncolytic Virus Cancer Therapy Therapies- ONCOS-102, gemcitabine, VRT106, CG0070, Keytruda, pembrolizumab, TILT-123, and others
For further information on the Oncolytic Virus Cancer Therapy Pipeline Therapeutics, reach out @ Oncolytic Virus Cancer Therapy Treatment Drugs [https://www.delveinsight.com/sample-request/oncolytic-virus-cancer-therapy-pipeline-insight-2021?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Content
* Introduction
* Executive Summary
* Oncolytic Virus Cancer Therapy: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Oncolytic Virus Cancer Therapy- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Olvi-Vec: Genelux Corporation
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* SND005: Jiangsu Sinorda Biomedicine
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I/II)
* AloCelyvir: Orgenesis
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* VCN-01: VCN Biosciences
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* SynOV 1.3: Beijing Syngentech
* Drug profiles in the detailed report.....
* Inactive Products
* Oncolytic Virus Cancer Therapy Key Companies
* Oncolytic Virus Cancer Therapy Key Products
* Oncolytic Virus Cancer Therapy- Unmet Needs
* Oncolytic Virus Cancer Therapy- Market Drivers and Barriers
* Oncolytic Virus Cancer Therapy- Future Perspectives and Conclusion
* Oncolytic Virus Cancer Therapy Analyst Views
* Oncolytic Virus Cancer Therapy Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=oncolytic-virus-cancer-therapy-pipeline-outlook-fda-approvals-clinical-trials-and-companies-2024]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Oncolytic Virus Cancer Therapy Pipeline Outlook, FDA Approvals, Clinical Trials and Companies 2024 here
News-ID: 3491629 • Views: …
More Releases from ABNewswire
Innervision Counselling Wins the 2024 Quality Business Award for The Best Marria …
Innervision Counselling Logo
Southampton, UK - 20 May, 2024 - Alison Curtis, a prominent marriage counsellor of Innervision Counselling, has, for the second year running, received the 2024 Quality Business Award for The Best Marriage Counsellor in Southampton, UK. This accolade acknowledges Innervision Counselling for its exceptional customer service, high-quality services, and overall business performance.
The Quality Business Awards annually acknowledges businesses exhibiting excellence within their industry. Selections are determined by taking…
Celiac Disease Market to Observe Rapid Growth During the Forecast Period (2024-2 …
The Celiac Disease Market report offers an in-depth understanding of the Celiac Disease, historical and forecasted epidemiology as well as the Celiac Disease market trends in the 7MM.
DelveInsight's "Celiac Disease Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Celiac Disease, historical and forecasted epidemiology as well as the Celiac Disease market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and…
Pine Valley Tree Service Wins the 2024 Quality Business Award for The Best Tree …
Kamloops, BC - May 17, 2024 - Pine Valley Tree Service, a prominent tree service company, has received the 2024 Quality Business Award for The Best Tree Service in Kamloops, BC. This accolade acknowledges Pine Valley Tree Service for its exceptional customer service, high-quality services, and overall business performance.
The Quality Business Awards annually acknowledges businesses exhibiting excellence within their industry. Selections are determined by taking into account their reputation, feedback…
Hemophilia B Pipeline Assessment, 2024 Updates | In-depth Insights into the Emer …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Hemophilia B pipeline constitutes key companies continuously working towards developing Hemophilia B treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
The Hemophilia B Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of…
More Releases for Oncolytic
Oncolytic Virus Market: Know Applications Supporting Impressive Growth
A new business intelligence report released by HTF MI with title "Global Oncolytic Virus Market Professional Survey Report 2019" is designed covering micro level of analysis by manufacturers and key business segments. The Global Oncolytic Virus Market survey analysis offers energetic visions to conclude and study market size, market hopes, and competitive surroundings. The research is derived through primary and secondary statistics sources and it comprises both qualitative and quantitative…
Oncolytic Virus Therapy Market Oncolytic Virus Therapy Clinical Pipeline Report …
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990
Report Table of Contents
Prologue to Oncolytic Virus
1.1 Outline of Oncolytic Virotherapy
1.2 Trail from Genesis to Biogenetics
Primer of Virotherapy in Malignancies
2.1 Oncolytic Viruses towards Cancer
2.2 Approaches for Targeting Tumor Cells
2.2.1 Pro Apoptotic Targeting
2.2.2 Translational Targeting
2.2.3 Transcriptional Targeting
2.2.4 Transductional Targeting
Mechanism…
Global Oncolytic Virus Therapy Report Highlight Market Opportunity & Insight On …
“Global Oncolytic Virus Therapy Market and Pipeline Outlook 2022” report analyzes ongoing clinical and non-clinical trends in the oncolytic virus therapy market. Currently there are 2 oncolytic virus therapies commercially available in the market. This report analyzes the ongoing clinical trial of 48 oncolytic virus therapies in clinical pipeline and gives comprehensive clinical insight on various parameters associated with the development of the oncolytic virus therapies. Most of the oncolytic…
Global Oncolytic Virus Therapy Market & Oncolytic Virus clinical Trials Outlook …
Advancements in human genomics over the last two decades have shown that cancer is mediated by somatic aberration in the host genome. This discovery has incited enthusiasm among cancer researchers; many now use therapeutic approaches in genetic manipulation to improve cancer regression and find a potential cure for the disease.
The dominant cancer treatment modalities such as chemotherapy, radiotherapy, and even targeted kinase inhibitors and mAbs are limited by low…
Global Oncolytic Virus Therapy Pipeline Analysis
Though still in nascent stages, Oncolytic viruses have shown immense opportunities and potential to be tapped in the future to improve the treatment of cancer and the lives of the patients. Immunotherapy, the umbrella for Oncolytic viruses would not offer cures, but survival solutions with significant importance. Also, the side effects of this therapy would be tolerable by the patients, which could thus become the most important approach to treat…
Global Oncolytic Virus Therapy Market and Pipeline Outlook 2022
“Global Oncolytic Virus Therapy Market and Pipeline Outlook 2022” report analyzes ongoing clinical and non-clinical trends in the oncolytic virus therapy market. Currently there are 2 oncolytic virus therapies commercially available in the market. This report analyzes the ongoing clinical trial of 48 oncolytic virus therapies in clinical pipeline and gives comprehensive clinical insight on various parameters associated with the development of the oncolytic virus therapies. Most of the oncolytic…
